Plozasiran Sales Forecast and Market Size Analysis - 2034 Report Reveals How Quarterly Dosing and Up to 74% Triglyceride Reduction Position Arrowhead's siRNA Across the 7MM

Summary

Market analysis report forecasts Plozasiran (Arrowhead's siRNA therapeutic) sales potential across seven major markets by 2034, highlighting its quarterly dosing regimen and up to 74% triglyceride reduction efficacy.